470 related articles for article (PubMed ID: 19753756)
1. Osteogenesis imperfecta.
Bhadada SK; Santosh R; Bhansali A; Upreti V; Dutta P
J Assoc Physicians India; 2009 Jan; 57():33-6. PubMed ID: 19753756
[TBL] [Abstract][Full Text] [Related]
2. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of osteogenesis imperfecta with bisphosphonates].
Tau C
Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
[TBL] [Abstract][Full Text] [Related]
4. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
5. Experience with bisphosphonates in osteogenesis imperfecta.
Glorieux FH
Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
[TBL] [Abstract][Full Text] [Related]
6. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
7. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
8. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L
Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883
[TBL] [Abstract][Full Text] [Related]
9. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
12. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Aström E; Magnusson P; Eksborg S; Söderhäll S
Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
[TBL] [Abstract][Full Text] [Related]
13. Osteogenesis imperfecta, current and future medical treatment.
Rauch F; Glorieux FH
Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
[TBL] [Abstract][Full Text] [Related]
14. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
[TBL] [Abstract][Full Text] [Related]
17. New trends in the treatment of osteogenesis imperfecta type III - own experience.
Jakubowska-Pietkiewicz E; Chlebna-Sokół D
Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
[TBL] [Abstract][Full Text] [Related]
19. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
20. Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study.
el-Sobky MA; Hanna AA; Basha NE; Tarraf YN; Said MH
J Pediatr Orthop B; 2006 May; 15(3):222-8. PubMed ID: 16601594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
